{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:43:35Z","timestamp":1793321015309,"version":"4.5.0"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T00:00:00Z","timestamp":1489449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CA A Cancer J Clinicians"],"published-print":{"date-parts":[[2017,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.wileyhealthlearning.com\/acs.aspx\">Answer questions and earn CME\/CNE<\/jats:ext-link>\n                  <\/jats:p>\n                  <jats:p>\n                    The revision of the eighth edition of the primary tumor, lymph node, and metastasis (TNM) classification of the American Joint Commission of Cancer (AJCC) for breast cancer was determined by a multidisciplinary team of breast cancer experts. The panel recognized the need to incorporate biologic factors, such as tumor grade, proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression prognostic panels into the staging system. AJCC levels of evidence and guidelines for all tumor types were followed as much as possible. The panel felt that, to maintain worldwide value, the tumor staging system should remain based on TNM anatomic factors. However, the recognition of the prognostic influence of grade, hormone receptor expression, and HER2 amplification mandated their inclusion into the staging system. The value of commercially available, gene\u2010based assays was acknowledged and prognostic input added. Tumor biomarkers and low Oncotype DX recurrence scores can alter prognosis and stage. These updates are expected to provide additional precision and flexibility to the staging system and were based on the extent of published information and analysis of large, as yet unpublished databases. The eighth edition of the AJCC TNM staging system, thus, provides a flexible platform for prognostic classification based on traditional anatomic factors, which can be modified and enhanced using patient biomarkers and multifactorial prognostic panel data. The eighth edition remains the worldwide basis for breast cancer staging and will incorporate future online updates to remain timely and relevant.\n                    <jats:bold>CA Cancer J Clin 2017;67:290\u2013303.<\/jats:bold>\n                    <jats:bold>\u00a9 2017 American Cancer Society.<\/jats:bold>\n                  <\/jats:p>","DOI":"10.3322\/caac.21393","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T17:34:38Z","timestamp":1489512878000},"page":"290-303","source":"Crossref","is-referenced-by-count":701,"title":["Breast Cancer\u2014Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual"],"prefix":"10.3322","volume":"67","author":[{"given":"Armando E.","family":"Giuliano","sequence":"first","affiliation":[{"name":"Executive Vice Chair, Surgery; Associate Director, Samuel Oschin Comprehensive Cancer Institute, Cedars\u2010Sinai Medical Center Los Angeles CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Connolly","sequence":"additional","affiliation":[{"name":"Professor of Pathology, Harvard Medical School, Beth Israel Deaconess Medical Center Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Edge","sequence":"additional","affiliation":[{"name":"Vice President, Healthcare Outcomes and Policy, Roswell Park Cancer Institute Buffalo NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Mittendorf","sequence":"additional","affiliation":[{"name":"Associate Professor, Department of Breast Surgical Oncology The University of Texas MD Anderson Cancer Center Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[{"name":"Professor of Medicine; Director, Breast Oncology and Clinical Trials Education University of California San Francisco, San Francisco CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence J.","family":"Solin","sequence":"additional","affiliation":[{"name":"Chairman, Department of Radiation Oncology Albert Einstein Healthcare Network, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"Weaver","sequence":"additional","affiliation":[{"name":"Professor of Pathology, University of Vermont Burlington VT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Winchester","sequence":"additional","affiliation":[{"name":"Associate Director, Kellogg Cancer Surgical Services NorthShore University HealthSystem Evanston IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel N.","family":"Hortobagyi","sequence":"additional","affiliation":[{"name":"Professor; Co\u2010Director, Breast Cancer Research Program The University of Texas MD Anderson Cancer Center Houston TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191367098"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2011.01.005"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4741.2010.01032.x"},{"key":"e_1_2_8_6_1","volume-title":"AJCC Cancer Staging Manual","author":"American Joint Committee on Cancer (AJCC)","year":"2017"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1730-9"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-2012-9"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2010.02.045"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-013-1965-1"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1991.tb00229.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.46.2.189-b"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.3174"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2013.3181"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.2289"},{"key":"e_1_2_8_16_1","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Breast Cancer Version 2.2016","author":"National Comprehensive Cancer Network (NCCN)","year":"2016"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510764"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","unstructured":"StemmerSM SteinerM RizelS et al.Real\u2010life analysis evaluating 1594\u2009N0\/Nmic breast cancer patients for whom treatment decisions incorporated the 21\u2010gene recurrence core result: 5\u2010year KM estimate for breast cancer specific survival with recurrence score results <30 is\u2009>\u200998% [P5\u201008\u201002]. Paper presented at: 2015 San Antonio Breast Cancer Symposium; December 8\u201012 2015; San Antonio TX.","DOI":"10.1158\/1538-7445.SABCS15-P5-08-02"},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","unstructured":"StemmerS SteinerM RizelS et al.First prospective outcome data in 930 patients with more than 5 year median follow up in whom treatment decisions in clinical practice have been made incorporating the 21\u2010gene recurrence score [abstract 1963]. Paper presented at: 2015 European Cancer Congress; September 25\u201029 2015; Vienna Austria.","DOI":"10.1016\/S0959-8049(16)30911-X"},{"key":"e_1_2_8_20_1","unstructured":"ShakS PetkovVI MillerDP et al.Breast cancer specific survival in 38 568 patients with node negative hormone receptor positive invasive breast cancer and Oncotype DX recurrence score results in the SEER database [abstract P5\u201015\u201001]. Paper presented at: 2015 San Antonio Breast Cancer Symposium; December 8\u201012 2015; San Antonio TX."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5383"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28082"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-2954-2"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.38"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602253"}],"container-title":["CA: A Cancer Journal for Clinicians"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.3322%2Fcaac.21393","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.3322\/caac.21393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:22:40Z","timestamp":1762363360000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.3322\/caac.21393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,14]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7,8]]}},"alternative-id":["10.3322\/caac.21393"],"URL":"https:\/\/doi.org\/10.3322\/caac.21393","archive":["Portico"],"relation":{},"ISSN":["0007-9235","1542-4863"],"issn-type":[{"value":"0007-9235","type":"print"},{"value":"1542-4863","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,14]]}}}